The prevention of breast cancer

British Journal of Surgery

Volumn 90, Issue 7, 2003, Pages 772-783

  Prichard, R S ^a   Hill, A D K ^a   Dijkstra, B ^a   McDermott, E W ^a   O'Higgins, N J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FENRETINIDE; MEGESTROL ACETATE; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; DARK ADAPTATION; DIET; DRY SKIN; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; LIVER TOXICITY; MASTECTOMY; MEDLINE; MORBIDITY; OVARIECTOMY; PREMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENICITY; URTICARIA;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; FORECASTING; GENES, BRCA1; GENES, BRCA2; HUMANS; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RETINOIDS; TAMOXIFEN;

EID: 0038675252     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4218     Document Type: Review

References (121)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Libby AL, Zellars RC, O'Connell P, Allred DC. Biological characteristics of pre-malignancy in breast disease. In Molecular Pathology of Early Cancer, Gadzar AF, Srivastava S, Henson DE (eds). IOS Press: Amsterdam, 1999; 79-95.
3. Henderson BE, Ross R, Bernstein L. Estrogens as a cause o human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988; 48: 246-253.
4. Vogel VG. Breast cancer risk factors and preventative approaches to breast cancer. In Cancer in Women, Kavanagh JJ, Singletary EV, Einhorn N, De Petrillo AD (eds). Blackwell Science: Oxford, 1998; 58-91.
5. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996; 17: 47-67.
6. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999; 130: 270-277.
7. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
8. Osborne CK, Schiff R, Fuqua SAW, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7(Suppl): 4338s-4342s.
9. Dickson RB, Lippman ME. Growth factors in breast cancer. Endocrine Rev 1995; 16: 559-589.
10. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999; 6: 235-243.
11. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999; 6: 75-92.
12. Sporn MB. Approaches to prevention of the epithelial cancer during the pre-neoplastic period. Cancer Res 1976; 36: 2699-2702.
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
14. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Brease and Bowel Project. JAMA 2001; 286: 2251-2256.
15. Hutchings O, Evans G, Fallowfield L, Cuzick J, Howell A. Effect of early American results on patients in a tamoxifen prevention trial (IBIS). International Breast Cancer Intervention Study. Lancet 1998; 352: 1222.
16. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989; 60: 126-131.
17. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB et al. Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990; 26: 680-684.
18. Powles T, Eeles R, Ashley SE, Easton D, Chang J, Dowsett M et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998; 352: 98-101.
19. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al. Prevention of breast cancer with tamoxifen: preliminary findings from the randomised trial among hysterecromised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-97.
20. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002; 359: 1122-1124.
21. Cuzick J. A brief review of the International Breast Cancer Intervention Study (IBCS), the other current breast cancer prevention trials, and proposals for furore trials. Ann N Y Acad Sci 2001; 949: 123-133.
22. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002; 360: 817-824.
23. Cummings SR, Eckert S, Krueger KA, Grady D, Powles T, Cauley JA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-2197.
24. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847-1856.
25. Rotmensz N, De Palo G, Formelli F, Costa A, Marubini E, Campa T et al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 1991; 27: 1127-1131.
26. Metcalfe KA, Goel V, Lickley L, Semple J, Narod SA. Prophylactic bilateral mastectomy: patterns of practice. Cancer 2002; 95: 236-242.
27. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
28. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl F Med 2001; 345: 159-164.
29. Hughes KS, Papa MZ, Whitney T, McLellan R. Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer 1999; 86: 2502-2516.
30. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L et al. Breast Cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-1479.
31. Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J et al. Outcome of preventative surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-1268.
32. Lippman SM, Benner SE, Hong WK. Chemoprevention. Strategies for the control of cancer. Cancer 1993; 72(Suppl): 984-990.
33. Vogel VG. Primary prevention of breast cancer. In The Breast: Comprehensive Management of Benign and Malignant Diseases (2nd edn), Bland KI, Copeland EM III (eds), vol. 1. WB Saunders: Philadelphia, 1998; 352-369.
34. Vogel VG. Chemoprevention: reducing breast cancer risk. In Management of Patients at High Risk for Breast Cancer, Vogel VG (ed.). Blackwell Science: Malden, 2001; 201-227.
35. Bertram JS, Kolonel LN, Meyskens FL Jr. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987; 47: 3012-3031.
36. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 45: 1-8.
37. Lerner LJ, Jordan VC. Development of antioestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990; 50: 4177-4189.
38. Jordan VC. Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst 1990; 82: 1662-1663.
39. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989; 37: 451-490.
40. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antioestrogen action. Pharmacol Rev 1998; 50: 151-196.
41. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
42. Pollak M, Constantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C et al. Effect of tamoxifen on serum insulinlike growth factor 1 levels in stage 1 breast cancer patients. J Natl Cancer Inst 1990; 82: 1693-1697.
43. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618.
44. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
45. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
46. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
47. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; ii: 282.
48. Powles TJ, Hardy JR, Ashley SE, Cosgrove D, Davey JB, Dowsett M et al. Chemoprevention of breast cancer. Breast Cancer Res Treat 1989; 14: 23-31.
49. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C et al. Projecting individualized probabilities of developing breast carcinoma for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
50. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
51. Cuzick J. Update on new studies in Europe. Eur J Cancer 2002; 38: S20.
52. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829-1846.
53. Chlebowski RT. Reducing the risk of breast cancer. N Engl J Med 2000; 343: 191-198.
54. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987; 47: 4020-4024.
55. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-758.
56. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996; 88: 123-125.
57. Jordan VC, Morrow M. Tamoxifen, raloxifene; and the prevention of breast cancer. Endocr Rev 1999; 20: 253-278.
58. Johnston SRD. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001; 7(Suppl): 4376s-4387s.
59. Gradishar WJ, Glusman JE, Vogel CL. Raloxifene HCL, a new endocrine agent, is active in oestrogen receptor positive metastatic breast cancer. Breast Cancer Res Treat 1997; 46: 53 (Abstract).
60. Jordan VC, Glusman JE, Eckert S. Raloxifene reduces incident primary breast cancers: integrated data from multicentre, double-blind, placebo-controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat 1998; 50: 227 (Abstract).
61. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63-69.
62. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG III et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20: 3328-3343.
63. Lippman ME, Krueger A, Eckert S, Sashegyi A, Walls EL, Jamal S et al. Indicators of lifetime oestrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001; 19: 3111-3116.
64. Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M et al. Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of oestrogen and raloxifene. J Womens Health 1998; 7: 839-847.
65. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL et al. N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979; 39: 1339-1346.
66. Mehta RG, Moon RC, Hawthorne M, Formelli F, Costa A. Distribution of fenretinide in the mammary, gland of breast cancer patients. Eur J Cancer 1991; 27: 138-141.
67. Formelli F, Clerici M, Campa T, DiMauro MG, Magni A, Mascotti G et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11: 2036-2042.
68. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-864.
69. Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC. Chemopreventative efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 1989; 49: 4472-4476.
70. McCormick DL, Mehta RG, Thompson CA, Dinger N, Caldwell JA, Moon RC. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res 1982; 42: 508-512.
71. McCormick DL, Moon RC. Retinoid - tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis 1986; 7: 193-196.
72. Lonning PE, Dowsett M, Powles TJ. Treatment of breast cancer with aromatase inhibitors - current status and future prospects. Br J Cancer 1989; 60: 5-8.
73. Lonning PE, Kragh LE, Erikstein B, Hagen A, Risberg T, Schlichting E et al. The potential for aromatase inhibition in breast cancer prevention. Clin Cancer Res 2001; 7(Suppl): 4423s-4428s.
74. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999; 6: 75-92.
75. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997; 52: 185-213.
76. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial and other malignancies. Endocr Rev 1998; 19: 593-607.
77. Brodie AM, Wing LY. In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-4-androstenedione. Steroids 1987; 50: 89-103.
78. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996; 14: 2000-2011.
79. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randontised trial. Lancet 2002; 359: 2131-2139.
80. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999; 6: 71-73.
81. Harris RE, Namboodiri KK, Farrar WB. Epidemiological study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1995; 2: 591-592.
82. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996; 7: 203-205.
83. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-2103.
84. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265-271.
85. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695.
86. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995; 72: 805-812.
87. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA 1 and BRCA 2. Cancer Genetics Study Consortium. JAMA 1997; 277: 997-1003.
88. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ et al. Germ-line BRCA1 mutation is an adverse prognostic factors in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997; 3: 2465-2469.
89. Hartmann LC, Schaid D, Sellers T. Bilateral prophylactic mastectomy in BRCA1/2 mutation carriers. Proc Am Assoc Cancer Res 2000; 41: 222 (Abstract).
90. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-454.
91. Goodnight JE Jr, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984; 26: 198-201.
92. Bowers DG Jr, Radlauer CB. Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with siliastic prostheses. Plast Reconstr Surg 1969; 44: 541-544.
93. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984; 148: 692-693.
94. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989; 13: 15-21.
95. Humphrey LJ. Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast: opinion or knowledge? Am J Surg 1983; 145: 311-312.
96. Borgen PI, Hill AD, Tran KN, Van Zee KJ, Massie MJ, Payne D et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998; 5: 603-606.
97. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Monogr 1995; 17: 33-35.
98. Parazzini F, Braga C, La Vecchia C, Negri E, Acerboni S, Franceschi S. Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol 1997; 90: 453-456.
99. Brinton LA, Schairer C, Hoover RN, Fraumeni JF Jr. Menstrual factors and risk of breast cancer. Cancer Invest 1988; 6: 245-254.
100. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997; 70: 150-154.
101. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-1196.
102. Kelsey JL, Berkowitz GS. Breast cancer epidemiology. Cancer Res 1988; 48: 5615-5623.
103. Howe GR, Hirohata T, Hislop TG, Iscovich JM, Yuan JM, Katsouyanni K et al. Dietary factors and risk of breast cancer: combined analysis of 12 case - control studies. J Natl Cancer Inst 1990; 82: 561-569.
104. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE. Dietary fat and the risk of breast cancer. N Engl J Med 1987; 316: 22-28.
105. Rohan TE, McMichael AJ, Baghurst PA. A population based case - control study of diet and breast cancer in Australia. Am J Epidemiol 1988; 128: 478-489.
106. Bennetts HW, Underwood EJ, Sheir FL. A specific breeding problem of sheep on subterranean clover pastures in western Australia. Aust Vet J 1964; 22: 2-12.
107. Barnes S, Grubbs C, Setchell KDR, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. In Mutagens and Carcinogens in the Diet, Pariza MW, Felton JS, Aeschbacher H-U, Sato S (eds). Wiley-Liss: New York, 1990; 239-253.
108. Messina M, Barnes S. The role of soy products in reducing risk o f cancer. J Natl Cancer Inst 1991; 83: 541-546.
109. Powles TJ. Breast cancer prevention. Oncologist 2002; 7: 60-64.
110. Berstein L, Ross RK, Henderson BE. Prospects for the primary prevention of breast cancer. Am J Epidemiol 1992; 135: 142-152.
111. Love RR. Breast cancer prevention. Oncologist 2002; 7: 100-102.
112. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000; 342: 564-571.
113. Fentiman IS. The endocrine prevention of breast cancer. Br J Cancer 1989; 60: 12-14.
114. Nayfield SG, Karp JE, Ford LG, Dorr FF, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450-1459.
115. Bruzzi P. Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue. BMJ 1998; 316: 1181-1182.
116. Lippman SM, Brown PH. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 1999; 21: 1809-1819.
117. Dunn BK, Ford LG. Prevention of breast cancer. Semin Breast Dis 2000; 3: 90-99.
118. Levine M, Moutquin JM, Walton R, Feighmer J. Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventative Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the care and treatment of Breast Cancer. CMAJ 2001; 164: 1681-1690.
119. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998; 352: 80-81.
120. Cuzick J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer 2000; 36: 1298-1302.
121. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 2001; 7(Suppl): 4413-4418.